CAM
TPTX

Cormorant Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Cormorant Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,484,220
Closed -$187M – 86
2022
Q2 		$187M Sell
2,484,220
-1,215,780
-33% -$54M 14.13% 1
2022
Q1 		$99.3M Buy
3,700,000
+675,000
+22% +$22.7M 7.63% 1
2021
Q4 		$144M Buy
3,025,000
+182,703
+6% +$8.17M 8.58% 2
2021
Q3 		$189M Sell
2,842,297
-194,745
-6% -$13.9M 7.67% 2
2021
Q2 		$237M Buy
3,037,042
+287,042
+10% +$21.2M 8.05% 1
2021
Q1 		$260M Buy
2,750,000
+357,703
+15% +$42.5M 5.8% 4
2020
Q4 		$292M Sell
2,392,297
-50,000
-2% -$5.48M 6.94% 1
2020
Q3 		$213M Sell
2,442,297
-295,000
-11% -$20.6M 8.2% 1
2020
Q2 		$177M Sell
2,737,297
-319,500
-10% -$18.4M 6.75% 1
2020
Q1 		$137M Sell
3,056,797
-339,853
-10% -$18M 6.34% 2
2019
Q4 		$212M Sell
3,396,650
-144,717
-4% -$6.89M 8.44% 1
2019
Q3 		$133M Buy
3,541,367
+419,000
+13% +$18.2M 8.11% 1
2019
Q2 		$127M Buy
+3,122,367
New +$111M 7.3% 1

Cormorant Asset Management's TPTX Position: Q3 2022 in Review

Cormorant Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 2,484,220 shares — an estimated $187M sold.

Cormorant Asset Management first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $292M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Cormorant Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cormorant Asset Management sold 2,484,220 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $187M.
  • Cormorant Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Cormorant Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $292M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.